Insight into the Significance of Foxp3 + tumor-infiltrating Lymphocytes in Squamous Cell Lung Cancer

Overview

Journal Clin Transl Oncol

Specialty Oncology

Date 2024 Feb 25

PMID 38402536

Authors

Kazu Shiomi

Masaaki Ichinoe

Ai Ushiwata

Koji Eshima

Ryo Nagashio

Shoko Hayashi

Dai Sonoda

Yasuto Kondo

Raito Maruyama

Masashi Mikubo

Yoshiki Murakumo

Yukitoshi Satoh

Affiliations

Soon will be listed here.

Abstract

Purpose: Although developing a better understanding of tumor-infiltrating Foxp3 + lymphocytes (Foxp3 + TILs) might provide essential knowledge to predict response to immunotherapy and prognosis, our current knowledge about Foxp3 + TILs is inadequate. This study investigated the prognostic significance of tumor-infiltrating Foxp3 + lymphocytes (Foxp3 + TILs) in squamous cell lung cancer (SQ-LC) objectively.

Methods: Among patients with SQ-LC surgically resected in our institution between 2011 and 2017, those with pathological stage IA3-IIIA were immunohistochemically studied to evaluate Foxp3 + TILs in their tumor stroma. The impact of Foxp3 + TILs on relapse-free survival (RFS) was analyzed with Kaplan-Meier survival analysis and multivariate analysis using a Cox proportional hazards model/Fine-Gray model.

Results: This study analyzed 100 patients. Multivariate analysis showed that a large number of Foxp3 + TILs in the stroma does not associate with a poor prognosis, rather that a large number of Foxp3 + TILs (≥ 64 cells) tend to be associated with a more favorable prognosis than a small number of Foxp3 + TILs (< 64 cells) (large vs small number: HR, 0.56; 95% CI, 0.17-1.83; P = 0.34). Exploratory analysis also showed that in the two populations divided by a difference in Foxp3 expression levels, similar trends to the main analysis were observed.

Conclusion: Our results showed that a large number of Foxp3 + TILs in the stroma may not associate with a poor prognosis in SQ-LC. To use the seemingly complicated information of Foxp3 + TILs as biomarkers, better understanding the diversity and heterogeneity of Foxp3 + TILs and analyzing their subpopulations that increase in the TME may be needed.

References

Ribas A, Wolchok J . Cancer immunotherapy using checkpoint blockade. Science. 2018; 359(6382):1350-1355. PMC: 7391259. DOI: 10.1126/science.aar4060. View

Chen D, Mellman I . Elements of cancer immunity and the cancer-immune set point. Nature. 2017; 541(7637):321-330. DOI: 10.1038/nature21349. View

Bruni D, Angell H, Galon J . The immune contexture and Immunoscore in cancer prognosis and therapeutic efficacy. Nat Rev Cancer. 2020; 20(11):662-680. DOI: 10.1038/s41568-020-0285-7. View

Nishikawa H, Sakaguchi S . Regulatory T cells in cancer immunotherapy. Curr Opin Immunol. 2014; 27:1-7. DOI: 10.1016/j.coi.2013.12.005. View

Shimizu J, Yamazaki S, Sakaguchi S . Induction of tumor immunity by removing CD25+CD4+ T cells: a common basis between tumor immunity and autoimmunity. J Immunol. 1999; 163(10):5211-8. View

Rabinovich G, Gabrilovich D, Sotomayor E . Immunosuppressive strategies that are mediated by tumor cells. Annu Rev Immunol. 2006; 25:267-96. PMC: 2895922. DOI: 10.1146/annurev.immunol.25.022106.141609. View

Sasada T, Kimura M, Yoshida Y, Kanai M, Takabayashi A . CD4+CD25+ regulatory T cells in patients with gastrointestinal malignancies: possible involvement of regulatory T cells in disease progression. Cancer. 2003; 98(5):1089-99. DOI: 10.1002/cncr.11618. View

Curiel T, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P . Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med. 2004; 10(9):942-9. DOI: 10.1038/nm1093. View

Bates G, Fox S, Han C, Leek R, Garcia J, Harris A . Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse. J Clin Oncol. 2006; 24(34):5373-80. DOI: 10.1200/JCO.2006.05.9584. View

10.

Ahmadzadeh M, Felipe-Silva A, Heemskerk B, Powell Jr D, Wunderlich J, Merino M . FOXP3 expression accurately defines the population of intratumoral regulatory T cells that selectively accumulate in metastatic melanoma lesions. Blood. 2008; 112(13):4953-60. PMC: 2954707. DOI: 10.1182/blood-2008-06-163048. View

11.

Saleh R, Elkord E . FoxP3 T regulatory cells in cancer: Prognostic biomarkers and therapeutic targets. Cancer Lett. 2020; 490:174-185. DOI: 10.1016/j.canlet.2020.07.022. View

12.

Salama P, Phillips M, Grieu F, Morris M, Zeps N, Joseph D . Tumor-infiltrating FOXP3+ T regulatory cells show strong prognostic significance in colorectal cancer. J Clin Oncol. 2008; 27(2):186-92. DOI: 10.1200/JCO.2008.18.7229. View

13.

Seminerio I, Descamps G, Dupont S, de Marrez L, Laigle J, Lechien J . Infiltration of FoxP3+ Regulatory T Cells is a Strong and Independent Prognostic Factor in Head and Neck Squamous Cell Carcinoma. Cancers (Basel). 2019; 11(2). PMC: 6406934. DOI: 10.3390/cancers11020227. View

14.

Miyao T, Floess S, Setoguchi R, Luche H, Fehling H, Waldmann H . Plasticity of Foxp3(+) T cells reflects promiscuous Foxp3 expression in conventional T cells but not reprogramming of regulatory T cells. Immunity. 2012; 36(2):262-75. DOI: 10.1016/j.immuni.2011.12.012. View

15.

Saito T, Nishikawa H, Wada H, Nagano Y, Sugiyama D, Atarashi K . Two FOXP3(+)CD4(+) T cell subpopulations distinctly control the prognosis of colorectal cancers. Nat Med. 2016; 22(6):679-84. DOI: 10.1038/nm.4086. View

16.

Chen J, Ye H, Xiao W, Mao Y, Ai S, Chen R . Increased Dysfunctional and Plastic Regulatory T Cells in Idiopathic Orbital Inflammation. Front Immunol. 2021; 12:634847. PMC: 8126653. DOI: 10.3389/fimmu.2021.634847. View

17.

Petersen R, Campa M, Sperlazza J, Conlon D, Joshi M, Harpole Jr D . Tumor infiltrating Foxp3+ regulatory T-cells are associated with recurrence in pathologic stage I NSCLC patients. Cancer. 2006; 107(12):2866-72. DOI: 10.1002/cncr.22282. View

18.

Shimizu K, Nakata M, Hirami Y, Yukawa T, Maeda A, Tanemoto K . Tumor-infiltrating Foxp3+ regulatory T cells are correlated with cyclooxygenase-2 expression and are associated with recurrence in resected non-small cell lung cancer. J Thorac Oncol. 2010; 5(5):585-90. DOI: 10.1097/JTO.0b013e3181d60fd7. View

19.

Tao H, Mimura Y, Aoe K, Kobayashi S, Yamamoto H, Matsuda E . Prognostic potential of FOXP3 expression in non-small cell lung cancer cells combined with tumor-infiltrating regulatory T cells. Lung Cancer. 2011; 75(1):95-101. DOI: 10.1016/j.lungcan.2011.06.002. View

20.

Jin Y, Zhang P, Li J, Zhao J, Liu C, Yang F . B7-H3 in combination with regulatory T cell is associated with tumor progression in primary human non-small cell lung cancer. Int J Clin Exp Pathol. 2016; 8(11):13987-95. PMC: 4713496. View